Abstract: An 4,5-bis(4-chlorophenyl)-1-hexyl-2-(3-hydroxy-4-methoxyphenyl)-1H-imidazole compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
November 8, 2023
Date of Patent:
May 14, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed
Abstract: The present invention relates to protein biocoacervates and biomaterials and the methods of making and using protein biocoacervates and biomaterials. More specifically the present invention relates to protein biocoacervates and biomaterials that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, coated medical devices (e.g. stents, valves . . . ), vessels, tubular grafts, vascular grafts, wound healing devices including protein suture biomaterials and biomeshes, dental plugs and implants, skin/bone/tissue grafts, tissue fillers, protein biomaterial adhesion prevention barriers, cell scaffolding and other biocompatible biocoacervate or biomaterial devices.
Abstract: Described is an aqueous liquid oral gliptin composition comprising a gliptin or a pharmaceutically acceptable salt or ester thereof, and an artificial non-sugar alcohol sweetening agent, the solution having a sugar alcohol content of less than 25 w/v %. The composition has an improved taste and stability as compared to known compositions. Also described is a method comprising the steps of heating 80-95 v/v % of the water to 40-65° C., admixing the antioxidant, and, if present, the chelating agent and buffering agent, optionally, cooling down to 25-35° C.
Type:
Grant
Filed:
October 23, 2020
Date of Patent:
April 2, 2024
Assignee:
AUTHENDA PHARMACEUTICALS AG
Inventors:
Ioannis Psarrakis, Konstantinos Lioumis
Abstract: Disclosed herein are compounds of formula I: and salts thereof. Also disclosed are compositions comprising compounds of formula I and methods using compounds of formula I.
Type:
Grant
Filed:
March 9, 2018
Date of Patent:
March 26, 2024
Assignee:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Inventors:
Edmond J. LaVoie, Ajit Parhi, Yongzheng Zhang
Abstract: Provided are an antioxidant complex for reducing the number of somatic cells in a livestock animal and a preparation method and application thereof. Active components of the preparation are melatonin (MT) having a centration of 2-30 g/L and vitamin C having a concentration of 1-14.3 g/L. The antioxidant complex provided in the present invention can effectively reduce the number of somatic cells in a diary cow and improve milk quality.
Abstract: Disclosed herein are pharmaceutical compositions comprising fencamfamine or fencamfamine related prodrug derivatives for targeted therapeutic applications and methods of synthesizing the compositions.
Type:
Grant
Filed:
April 14, 2020
Date of Patent:
March 5, 2024
Assignee:
Praxis Bioresearch, LLC
Inventors:
Sandeep Patil, Ron Bihovsky, Steven A Smith, Yuhua Ji, Valentino Stella, Daniel D. Long, Daniel Marquess
Abstract: Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.
Abstract: In general, the invention relates to pharmaceutical compositions comprising (R)-oxybutynin and a norepinephrine reuptake inhibitor (NRI) and methods of treating Sleep Apnea comprising administering (R)-oxybutynin and a norepinephrine reuptake inhibitor (NRI). In some embodiments, the NRI is atomoxetine.
Type:
Grant
Filed:
January 30, 2019
Date of Patent:
February 27, 2024
Assignee:
APNIMED, INC. (DELAWARE)
Inventors:
Lawrence G. Miller, Barry Wohl, Walter J. Lunsmann
Abstract: A method of measuring a wet friction of a bundle of hair, using a system which includes a friction probe having a contact surface and fitted with a weight in the range of from 10 g to 500 g, inclusive, a means for securing the bundle of hair, and a water bath, the friction probe being connected to a texture analyser, the method including the step of i) providing a bundle of hair fibres. The method also includes the steps of ii) aligning the bundle of hair fibres; iii) securing the bundle of hair fibres; iv) immersing the bundle of hair fibres under water in the water bath; v) contacting the bundle of hair fibres with the contact surface of the friction probe, which is fitted with the weight; vi) moving the probe along the hair fibres; and vii) recording the friction generated under step vi).
Type:
Grant
Filed:
March 21, 2018
Date of Patent:
January 23, 2024
Assignee:
Conopco, Inc.
Inventors:
Andrew Anthony Howard Barnes, Fraser Ian Bell, Colin Christopher David Giles, Sophia Paraskevi Clare Moghadam, Rongrong Zhou
Abstract: The present invention relates to stable pharmaceutical compositions of dihydroergotamine mesylate or other pharmaceutically acceptable salts thereof and methods for preparing the compositions particularly for the treatment of migraine headaches. The invention further relates to stable injectable composition comprising dihydroergotamine or its pharmaceutically acceptable salts thereof, wherein the composition has a pH from about 5.0 to about 6.0. Further, the present invention relates to a method of treating migraine comprising providing a stable pharmaceutical composition for parenteral administration comprising dihydroergotamine mesylate, wherein the pH of the composition ranges from 5.0 to 6.0 and, wherein the composition comprises no greater than 3% of total impurities as determined by HPLC.
Abstract: Provided herein are treatments for reducing pain in dogs. The treatments generally comprise a combination of an opioid compound, such as methadone, and an azole compound, such as fluconazole. The treatments may further comprise an opioid abuse deterrent that advantageously inhibits opioid effects in humans while maintaining desirable analgesic effects in dogs. Additionally, the treatments provided herein avoid the undesirable side effects of prior art opioid treatments for dogs. The treatments may be administered as separate doses or in a single formulation product for improved compliance. The treatments have wide use potential in dogs from perioperative patients to inpatients and outpatients and may be used, for example, for sedation in minor procedures, analgesia, and decreasing temperature in canine patients.
Type:
Grant
Filed:
September 5, 2018
Date of Patent:
October 3, 2023
Assignee:
Kansas State University Research Foundation
Inventors:
Stanley KuKanich, Katherine KuKanich, Charles W. Locuson, David Rankin
Abstract: An extended release tablet (ERT), having phentermine or a pharmaceutically acceptable salt thereof, and one or more of a wax and a pharmaceutically acceptable excipient selected from among one or more of a fatty acid, a bulking agent, a lubricant and the like is disclosed. A process for its preparation is also disclosed.
Abstract: The invention is directed to stable liquid pharmaceutical compositions comprising, consisting of, or consisting essentially of bendamustine, at least one cyclodextrin, at least one non-aqueous solvent, at least about 2% water v/v of the composition, and at least one antioxidant, and their use for treating cancers, their preparation, and dosage forms containing them.
Abstract: Disclosed herein are pharmaceutical compositions comprising fencamfamine or fencamfamine related prodrug derivatives for targeted therapeutic applications and methods of synthesizing the compositions.
Type:
Grant
Filed:
April 14, 2020
Date of Patent:
August 22, 2023
Assignee:
Praxis Bioresearch, LLC
Inventors:
Sandeep Patil, Ron Bihovsky, Steven A Smith, Yuhua Ji, Valentino Stella, Daniel D. Long, Daniel Marquess
Abstract: Provided is a rapid release tablet excellent in binding capability and disintegrability and also excellent in storage stability and the like. More specifically, provided are a granulated composite comprising low-substituted hydroxypropyl cellulose having a degree of hydroxypropoxy substitution of from 5 to 16% by weight and D-mannitol, wherein the D-mannitol contains 0.9% by weight or less of D-sorbitol; a rapid release tablet comprising the granulated composite and a drug; and a method for producing a granulated composite comprising the steps of: mixing low-substituted hydroxypropyl cellulose having a degree of hydroxypropoxy substitution of from 5 to 16% by weight, first D-mannitol, and water to obtain an aqueous dispersion, and granulating while adding the aqueous dispersion to second D-mannitol, wherein the first D-mannitol and the second D-mannitol contain 0.9% by weight or less of D-sorbitol in total.
Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
Abstract: Applications of spermine or its pharmaceutically acceptable derivative in preparation of an SAICAR synthetase activity interfering agent or inhibitor. Applications of spermine or its pharmaceutically acceptable derivative in preparation of antitumor drug.
Abstract: The present invention provides a compound of formula IA or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Type:
Grant
Filed:
January 28, 2019
Date of Patent:
June 13, 2023
Assignee:
NOVARTIS AG
Inventors:
Atwood Kim Cheung, Natalie Dales, Timothy Brian Hurley